Bradley Miller
Pediatric Endocrinology · Minneapolis, MNNPI 1184633059
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Novo Nordisk Health Care AG at 26.3% of the total. Among pediatric endocrinology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $1303.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk Health Care AG$122K
- Biomarin Pharmaceutical Inc.$61K
- Novo Nordisk AS$41K
- Novo Nordisk$40K
- Pfizer$40K
- Tolmar, Inc.$31K
- plus $131K from 18 others
Across 459 payments — averaging $1928.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$266K
- Novo Nordisk AS$192K
- AbbVie$155K
- OPKO Pharmaceuticals, LLC$87K
- Ascendis Pharma Endocrinology Inc$70K
- Biomarin Pharmaceutical Inc.$34K
- plus $81K from 4 others
What the payments were for
- Consulting fees$229,14349%
- Speaking & faculty fees$112,78624%
- Travel & lodging$110,31524%
- Food & beverage$10,6792%
- Education$2,2960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk Health Care AG | 64 | $122,429 |
| Biomarin Pharmaceutical Inc. | 86 | $60,768 |
| Novo Nordisk AS | 20 | $40,993 |
| Novo Nordisk | 44 | $39,689 |
| Pfizer | 22 | $39,578 |
| Tolmar, Inc. | 14 | $31,245 |
| Ascendis Pharma Endocrinology Inc | 23 | $27,086 |
| Hexal AG | 15 | $20,237 |
| Tolmar Pharmaceuticals, Inc. | 14 | $17,913 |
| Soleno Therapeutics, Inc. | 11 | $14,802 |
| Sanofi | 7 | $9,802 |
| Sanofi-aventis U.S. LLC | 6 | $8,593 |
| Amgen | 11 | $7,957 |
| Eton Pharmaceuticals, Inc. | 3 | $4,824 |
| Vistapharm, Inc. | 1 | $4,000 |
| Shire North American Group Inc | 4 | $3,982 |
| AstraZeneca | 1 | $2,975 |
| Endo Pharmaceuticals Inc. | 2 | $2,405 |
| Merck Kgaa | 1 | $2,220 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,000 |
| Sandoz | 4 | $1,512 |
| Azurity Pharmaceuticals, Inc. | 1 | $128 |
| Rhythm Pharmaceuticals, Inc. | 1 | $60 |
| AbbVie | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Norditropin$87,380
- Sogroya$49,533
- FENSOLVI$44,392
- OMNITROPE$21,394
- GENOTROPIN$19,973
- VOXZOGO 1.2mg$18,191
- NGENLA$15,428
- SKYTROFA$13,455
- VYKAT XR$10,671
- TZIELD$8,504
- PROCYSBI$7,813
- INCRELEX$6,000
- Alkindi$4,795
- ELIGARD$4,366
- Thyquidity$4,000
- KHINDIVI$4,000
- Diazoxide Choline Controlled Release (DCCR)$3,948
- ALDURAZYME$3,377
- SUPPRELIN$2,405
- Tresiba$185
How this compares
$465,219 in reported general payments places this provider in the 95th percentile of 25 pediatric endocrinology providers in Minnesota.
Other pediatric endocrinology in Minneapolis
- Antoinette MoranMinneapolis$63K
- Melena BellinMinneapolis$56K
- Brandon NathanMinneapolis$11K
- Megan BensignorMinneapolis$886
- Silpa NadellaMinneapolis$371
- Sarah MurphyMinneapolis$208
- Matthew WiseMinneapolis$148
- Eric BombergMinneapolis$60
- Elwaseila HamdounMinneapolis$18
- Anna PetrykMinneapolis$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.